|
|
 |
|
Viewing report
|
|
|
|
Biogen Idec Inc.
Standard & Poors, April 2011
Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.
Research Type: Full Analysis
Abstract
Multiple sclerosis (MS) drug Avonex continues to hold a leading market share in the large MS category; Tysabri is a major growth factor for Biogen Idec and provides the company with the opportunity to extend its MS franchise; Cancer treatment Rituxan is the leading drug used to treat non-Hodgkin's lymphoma (NHL) and faces very little competition; and Biogen Idec's net debt-free financial profile, large cash balances, and growing free cash flows provide significant flexibility to conduct pipeline enhancing transactions. The company has a high reliance on the sales of just two drugs, Avonex and Rituxan; and Biogen Idec has a relatively light near-term product pipeline. The ratings on Cambridge, Mass.-based biotechnology company Biogen Idec Inc. reflect what Standard and Poor's...
Companies mentioned in this report are: Biogen Idec Inc.
Action: Review
|
|
|
|
